78 related articles for article (PubMed ID: 2071895)
1. Site-directed mutagenesis of the region around Cys-241 of complement component C2. Evidence for a C4b binding site.
Horiuchi T; Macon KJ; Engler JA; Volanakis JE
J Immunol; 1991 Jul; 147(2):584-9. PubMed ID: 2071895
[TBL] [Abstract][Full Text] [Related]
2. Evidence for the involvement of arginine 462 and the flanking sequence of human C4 beta-chain in mediating C5 binding to the C4b subcomponent of the classical complement pathway C5 convertase.
Ebanks RO; Isenman DE
J Immunol; 1995 Mar; 154(6):2808-20. PubMed ID: 7876551
[TBL] [Abstract][Full Text] [Related]
3. A single arginine to tryptophan interchange at beta-chain residue 458 of human complement component C4 accounts for the defect in classical pathway C5 convertase activity of allotype C4A6. Implications for the location of a C5 binding site in C4.
Ebanks RO; Jaikaran AS; Carroll MC; Anderson MJ; Campbell RD; Isenman DE
J Immunol; 1992 May; 148(9):2803-11. PubMed ID: 1573269
[TBL] [Abstract][Full Text] [Related]
4. Amino acid residues 1101-1105 of the isotypic region of human C4B is important to the covalent binding activity of complement component C4.
Reilly BD; Levine RP; Skanes VM
J Immunol; 1991 Nov; 147(9):3018-23. PubMed ID: 1919003
[TBL] [Abstract][Full Text] [Related]
5. Evidence for a C4b binding site on the C2b domain of C2.
Oglesby TJ; Accavitti MA; Volanakis JE
J Immunol; 1988 Aug; 141(3):926-31. PubMed ID: 3397535
[TBL] [Abstract][Full Text] [Related]
6. Probing the C1q-binding site on human C-reactive protein by site-directed mutagenesis.
Agrawal A; Volanakis JE
J Immunol; 1994 Jun; 152(11):5404-10. PubMed ID: 8189060
[TBL] [Abstract][Full Text] [Related]
7. Active sites in complement component C3 mapped by mutations at indels.
Ogata RT; Ai R; Low PJ
J Immunol; 1998 Nov; 161(9):4785-94. PubMed ID: 9794410
[TBL] [Abstract][Full Text] [Related]
8. Effects of buried charged groups on cysteine thiol ionization and reactivity in Escherichia coli thioredoxin: structural and functional characterization of mutants of Asp 26 and Lys 57.
Dyson HJ; Jeng MF; Tennant LL; Slaby I; Lindell M; Cui DS; Kuprin S; Holmgren A
Biochemistry; 1997 Mar; 36(9):2622-36. PubMed ID: 9054569
[TBL] [Abstract][Full Text] [Related]
9. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
10. cDNA cloning and expression of human complement component C2.
Horiuchi T; Macon KJ; Kidd VJ; Volanakis JE
J Immunol; 1989 Mar; 142(6):2105-11. PubMed ID: 2493504
[TBL] [Abstract][Full Text] [Related]
11. Contribution of the complement control protein modules of C2 in C4b binding assessed by analysis of C2/factor B chimeras.
Xu Y; Volanakis JE
J Immunol; 1997 Jun; 158(12):5958-65. PubMed ID: 9190950
[TBL] [Abstract][Full Text] [Related]
12. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP
Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650
[TBL] [Abstract][Full Text] [Related]
13. Active sites in complement components C5 and C3 identified by proximity to indels in the C3/4/5 protein family.
Low PJ; Ai R; Ogata RT
J Immunol; 1999 Jun; 162(11):6580-8. PubMed ID: 10352274
[TBL] [Abstract][Full Text] [Related]
14. The effects of iodine and thiol-blocking reagents on complement component C2 and on the assembly of the classical-pathway C3 convertase.
Kerr MA; Parkes C
Biochem J; 1984 Apr; 219(2):391-9. PubMed ID: 6611150
[TBL] [Abstract][Full Text] [Related]
15. Substitution of two amino acids confers C3b binding to the C4b binding site of CR1 (CD35). Analysis based on ligand binding by chimpanzee erythrocyte complement receptor.
Subramanian VB; Clemenza L; Krych M; Atkinson JP
J Immunol; 1996 Aug; 157(3):1242-7. PubMed ID: 8757632
[TBL] [Abstract][Full Text] [Related]
16. Reductase domain cysteines 1048 and 1114 are critical for catalytic activity of human endothelial cell nitric oxide synthase as probed by site-directed mutagenesis.
Zhang JL; Patel JM; Li YD; Block ER
Biochem Biophys Res Commun; 1996 Sep; 226(1):293-300. PubMed ID: 8806629
[TBL] [Abstract][Full Text] [Related]
17. C3 convertases of complement. Molecular genetics, structure and function of the catalytic domains, C2 and B.
Volanakis JE
Year Immunol; 1989; 4():218-30. PubMed ID: 2648703
[No Abstract] [Full Text] [Related]
18. Characterization of a dinucleotide-binding site in monoamine oxidase B by site-directed mutagenesis.
Kwan SW; Lewis DA; Zhou BP; Abell CW
Arch Biochem Biophys; 1995 Jan; 316(1):385-91. PubMed ID: 7840641
[TBL] [Abstract][Full Text] [Related]
19. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
Diefenbach RJ; Isenman DE
J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
[TBL] [Abstract][Full Text] [Related]
20. Investigation of a catalytic zinc binding site in Escherichia coli L-threonine dehydrogenase by site-directed mutagenesis of cysteine-38.
Johnson AR; Chen YW; Dekker EE
Arch Biochem Biophys; 1998 Oct; 358(2):211-21. PubMed ID: 9784233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
